Is it really unacceptable that the Oxford vaccine is 70% effective?

November 23rd, AstraZenecom announced the results of phase III clinical trials of its new coronavirus vector vaccine, a partnership with Oxford University, with an average effective rate of 70 per cent.
is a far from the two companies that have announced the results of the trials, AstraZeneta's share price has fallen 3.8pc instead of the vaccine being shown to work.
If the 70 per cent effectiveness rate is "colored" by the stock market, then some media "escape" reports are also suggesting that 70 per cent is "unacceptable" - more than
media outlets reported the interim results of the clinical trial under the headline "AstraZeneta's new crown vaccine is 90 per cent effective". It seems that the new crown vaccine is less than 90% effective and will not be available.
is it really so unacceptable that the new coronavirus", the Oxford vaccine, is 70 per cent effective?there are two versions of data on the Oxford vaccine?
, the vaccine, named AZD1222, took two drug-giving options. One is half the dose of the first shot and the second is given at full dose, which shows a 90 per cent effective rate when the medium-term results are revealed, while the other is given at half the dose, both times at full dose, with an effective rate of 62 per cent. However, as a medium-term result, the two drug-giving programmes were calculated uniformly at 70 per cent.
", the dose of the drug was explored during animal trials. "Lee Zhongming, a former FDA examiner and vaccine expert, still remembers the oxford vaccine research and development team's previous paper on animal trials, "and the results of this human trial show that the vaccine's effectiveness is consistent with that of animals." "
" animals have a 'seed', hastened to the human body to verify, the result is really so, this is very convincing in terms of effectiveness. Li Zhongming said.
"understanding the law" means more control and, to some extent, clarity of the system for humans who can't "drill in" to see how vaccines work.
Li Zhongming explained that the adenovirus vector vaccine, the code of the new coronavirus protrusion protein gene into the body after the expression of antigens to produce immunity, the first shot of the vaccine came in, the immune system first of all to produce an immune response to the vector, to eliminate it, and as a vector of the adenovirus in the body to expand, enhance the effectiveness of the vaccine, if the first dose of too strong immune response, will inhibit the strengthening of the second immune action. If the dose is small, the resulting resistance is small, and after constantly "pulling the saw" and "negotiating", after a month to come back to a large dose, its immune response immediately up, the effect is better.
is a unique feature of the adenovirus vector vaccine, and it is clear that it is different from the principle of the mRNA vaccine. "Li Zhongming once again stressed that, in fact, the workings of each technical route are very different, the wake-up of the body's immune system is very complex, vaccine efficiency this number does not tell the whole problem." efficiency, vaccination rate, length of protection, is indispensable. At the Lancet-Chinese Medicine
Conference on Medicine and Health on 24 November, Sir Roy Anderson, a professor at Imperial College London, explained the ultimate goal of judging vaccines to form group immunity, minimize mortality and severity.
"We want to get group immunity through immunization," he said. Roy Anderson says vaccines are an effective way to get group immunity. If vaccine is the "weapon" to win the battle against human poison, whether it can help human beings to achieve mass immunization will be judged by its "good" and "bad" standards.
this, Roy Anderson gives the calculation method. Each virus has a different R0 (the basic number of infections, i.e. the average infection of each infected person in the outbreak is transmitted to several people), the new coronavirus R0 is 2.5-4.8, the
virus is 11-12, SARS is 4-5 ... In the premise that there is no other means to block the transmission path, in order to form a group immunization, the vaccine needs to be achieved: vaccination rate, effectiveness, 1-1/R0.
If the new crown vaccine is 90% effective, then the vaccination rate of 66.7% can reach the group immunization (R0 s 2.5), if the efficiency is 70%, then the vaccination rate of 85.7% can reach the group immunization. It can be seen that under the premise of vaccine approval, improve vaccination rate, 70% of the effective vaccine can still achieve the goal of mass immunization.
in the time dimension, vaccines need further research and trials. "Studies of the protection time of other coronavirus vaccines have shown that the protection time of vaccines is relatively short." Roy Anderson says further research is needed, so the first-year vaccination strategy is different from the one used to achieve system balance.
the new crown vaccine will require "years of planning", which must also include special groups such as the elderly and newborn babies, and will require a huge systematic project.
on the regulatory front, FDA Director Stephen Hahn said Tuesday, "The FDA will not authorize vaccines solely on the basis of press releases (effective rate figures given), a clinical study of tens of thousands of people, and the FDA will review data from all patients and carefully verify the analysis calculations to ensure that we agree with the conclusions on safety and technology obtained by the companies involved." This
means that the efficiency data published by the different new crown vaccines still need to be verified by authorities as a basis for immunization strategy planning.